loading
Bullfrog AI Holdings Inc stock is currently priced at $3.15, with a 24-hour trading volume of 22,000. It has seen a +1.29% increased in the last 24 hours and a -1.56% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $3.11 pivot point. If it approaches the $3.17 resistance level, significant changes may occur.
Previous Close:
$3.11
Open:
$3.08
24h Volume:
22,000
Market Cap:
$24.45M
Revenue:
-
Net Income/Loss:
$-5.36M
P/E Ratio:
-4.1037
EPS:
-0.7676
Net Cash Flow:
$-6.00M
1W Performance:
+8.25%
1M Performance:
-1.56%
6M Performance:
+9.38%
1Y Performance:
-37.38%
1D Range:
Value
$3.04
$3.1699
52W Range:
Value
$2.36
$8.35

Bullfrog AI Holdings Inc Stock (BFRG) Company Profile

Name
Name
Bullfrog AI Holdings Inc
Name
Phone
240 658 6710
Name
Address
325 Ellington Blvd, Unit 317, Gaithersburg
Name
Employee
2
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
BFRG's Discussions on Twitter

Bullfrog AI Holdings Inc Stock (BFRG) Financials Data

Bullfrog AI Holdings Inc (BFRG) Net Income 2024

BFRG net income (TTM) was -$5.36 million for the quarter ending December 31, 2023, a -91.11% decrease year-over-year.
loading

Bullfrog AI Holdings Inc (BFRG) Cash Flow 2024

BFRG recorded a free cash flow (TTM) of -$6.00 million for the quarter ending December 31, 2023, a -558.83% decrease year-over-year.
loading

Bullfrog AI Holdings Inc (BFRG) Earnings per Share 2024

BFRG earnings per share (TTM) was -$0.89 for the quarter ending December 31, 2023, a -76.80% decline year-over-year.
loading
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
$17.57
price down icon 0.26%
$31.58
price down icon 1.52%
health_information_services EVH
$27.03
price down icon 1.39%
health_information_services TXG
$27.50
price up icon 4.60%
$24.20
price down icon 0.47%
health_information_services RCM
$12.47
price up icon 0.15%
Cap:     |  Volume (24h):